Altimmune to Participate at Two Upcoming Conferences

Rhea-AI Summary

Altimmune, Inc. (Nasdaq: ALT) will be represented by Dr. Scott Harris, Chief Medical Officer, at two upcoming conferences: BTIG Obesity Health Forum and GLP-1-Based Therapeutics Summit. The presentations will focus on emerging therapeutics and the use of GLP-1s in treating MASH & Fatty Liver Disease.

GAITHERSBURG, Md., May 01, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer at Altimmune, will present on behalf of the Company at the following two upcoming conferences:

• BTIG Obesity Health Forum (Virtual Conference)
  Title: Emerging Therapeutics Panel
  Wednesday, May 8, 2024
  Panel Discussion at 4:00 pm Eastern Time

• GLP-1-Based Therapeutics Summit (Philadelphia, PA)   
  
  
  • Title: Focusing on the Use of GLP-1s in Treating MASH & Fatty Liver Disease
    Wednesday, May 15, 2024
    Presentation at 10:00 am Eastern Time
    
    
  • Title: Attaining Product Differentiation through Improved Patient Segmentation & Efficiency
    Thursday, May 16, 2024
    Presentation at 1:30pm Eastern Time

About Altimmune

Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter

Altimmune Investor Contact:
Richard Eisenstadt
Chief Financial Officer
Phone: 240-654-1450
reisenstadt@altimmune.com

Investor Contact:
Lee Roth
Burns McClellan
Phone: 646-382-3403
lroth@burnsmc.com

Julia Weilman
Burns McClellan
Phone: 646-732-4443
jweilman@burnsmc.com

Media Contact:
Danielle Cantey
Inizio Evoke, Biotech
Phone: 619-826-4657
Danielle.cantey@inizioevoke.com

FAQ

When and where will Altimmune participate in upcoming conferences?

Altimmune, Inc. (Nasdaq: ALT) will participate in the BTIG Obesity Health Forum on May 8, 2024, and the GLP-1-Based Therapeutics Summit on May 15 and May 16, 2024.

Who will represent Altimmune at the conferences?

Dr. Scott Harris, Chief Medical Officer at Altimmune, will represent the company at the upcoming conferences.

What will be the focus of Altimmune's presentations at the conferences?

The presentations will focus on emerging therapeutics and the use of GLP-1s in treating MASH & Fatty Liver Disease.

What is the stock symbol for Altimmune?

The stock symbol for Altimmune is NASDAQ: ALT.